Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

ional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to follow)GenVec
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
2. GenVec Appoints Cynthia Collins as President and CEO
3. GenVec Reports Inducement Award
4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
6. GenVec Reports Second Quarter 2012 Financial Results
7. GenVec Reports Third Quarter 2012 Financial Results
8. GenVec to Present at 25th Annual ROTH Conference
9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis ... Foundation (HNF), both philanthropies, announced today the creation ... for the treatment of the rare disease known ... Alliance announced its alliance model earlier this month. ... demonstration of a collaborative model where researchers and ...
(Date:10/19/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), ... services to office-based dental, animal health and medical practitioners, ... Supply, Inc., a leading full-service provider of dental consumables, ... entrance into Japan , the world,s ... 28 the number of countries in which the Company ...
(Date:10/17/2014)... , Oct. 17, 2014 With ... Medical Affairs function has come across several challenges ... efficiently and managing globalization.  The ... LLC is dedicated to providing benchmarking and best ... Affairs Consortium is a service composed of three ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2
... Nov. 1 The Phase 3 results from the ... therapy regimens. The study reports an improvement in treatment ... 2 studies, and demonstrates an increase in sustained viral ... The primary endpoint for this study was SVR 24 ...
... Nov. 1, 2010 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 2Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 4Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 5Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 6Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 7Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 8Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 9Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 10Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 11Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 12
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that it will release its financial results for,the quarter ... after,the close of the U.S. financial markets. CryoCor ... at 5:00 p.m. ET /,2:00 p.m. PT on November ...
... With Business Objectives, Watson ... Survey Finds, WASHINGTON, Nov. 7 With continuing ... offer financial,incentives to reward workers who adopt healthy lifestyles, ... global consulting firm, and the,National Business Group on Health, ...
... 7 A cholesterol-lowering drug appears to disrupt sleep ... Heart Associations Scientific Sessions 2007. , The findings are ... and may have adverse health consequences, such as promoting ... lead author of the study and an associate professor ...
... Nov. 7 Exposing estrogen-sensitive breast cancer cells to ... sewer and industrial waste causes the cells to multiply, ... at the annual meeting of the American Public Health ... will be presented at a special session on Contaminants ...
... Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. 7 ... Philip Morris and R.J. Reynolds tobacco companies have,again ... by defeating a,ballot initiative to increase Oregon,s cigarette ... companies will profit by selling more cigarettes,while Oregonians ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... Operating Officer, will present at the JMP Securities,Healthcare ... 2007 at 2:30 p.m.,Eastern Time. To access ... visit the Investor Relations section of Genomic Health,s,website ...
Cached Medicine News:Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2Health News:Extracts of catfish caught in polluted waters cause breast cancer cells to multiply 2Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Genomic Health to Present at JMP Securities Healthcare Focus Conference 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
Medicine Products: